This grant, offered by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Office of Dietary Supplements (ODS), is for supporting exploratory and developmental clinical research. Specifically, it targets the prevention or treatment of diabetes, obesity, endocrine, and genetic metabolic diseases, including cystic fibrosis. The program aims to facilitate the initiation of short-term clinical studies, allowing new ideas with high clinical impact to be investigated without extensive preliminary data requirements. Priority is given to studies testing novel prevention strategies, interventions, or therapy combinations. Ultimately, this NIDDK and ODS grant seeks to translate promising laboratory research developments into practical clinical applications for these critical health areas, utilizing the NIH Exploratory/Developmental (R21) mechanism.
Opportunity ID: 46071
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PA-09-133 |
| Funding Opportunity Title: | Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Food and Nutrition Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 17, 2009 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | May 07, 2012 |
| Current Closing Date for Applications: | May 07, 2012 |
| Archive Date: | Jun 07, 2012 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $200,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled “Additional Information on Eligibility” for clarification) Private institutions of higher education Special district governments Public housing authorities/Indian housing authorities City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Public and State controlled institutions of higher education State governments County governments Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Purpose. This FOA, issued by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Office of Dietary Supplements (ODS) of the National Institutes of Health, encourages exploratory/developmental clinical research related to the prevention or treatment of diabetes, obesity and endocrine and genetic metabolic diseases. The Pilot and Feasibility Clinical Research Grants Program is designed to allow initiation of exploratory, short-term clinical studies, so that new ideas may be investigated without stringent requirements for preliminary data. The short-term studies should focus on research questions that are likely to have high clinical impact. They can include testing a new prevention strategy, a new intervention, or unique combinations of therapies. A high priority is the use of such studies to help stimulate the translation of promising research developments from the laboratory into clinical practice in diabetes, endocrine diseases and genetic metabolic diseases, including cystic fibrosis. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PA-09-133.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.847 | ADOBE-FORMS-A | Adobe-Forms-A | PKG00011102 | May 16, 2009 | Feb 20, 2010 | View |
| 93.847 | ADOBE-FORMS-B | Use for submissions intended for due dates of January 25, 2010 and beyond | PKG00015513 | Dec 21, 2009 | Oct 30, 2010 | View |
| 93.847 | ADOBE-FORMS-B1 | Supersedes ADOBE-FORMS-B | PKG00022218 | Oct 30, 2010 | May 07, 2012 | View |
Package 1
Mandatory forms
46071 RR_SF424-1.1.pdf
46071 RR_KeyPersonExpanded-1.1.pdf
46071 RR_OtherProjectInfo-1.1.pdf
46071 RR_PerformanceSite-1.1.pdf
46071 PHS398_CoverPageSupplement-1.1.pdf
46071 PHS398_ResearchPlan-1.1.pdf
46071 PHS398_Checklist-1.1.pdf
Optional forms
46071 PHS398_CoverLetter-1.1.pdf
46071 RR_Budget-1.1.pdf
46071 RR_SubawardBudget-1.2.pdf
Package 2
Mandatory forms
46071 RR_SF424_1_2-1.2.pdf
46071 PerformanceSite_1_3-1.3.pdf
46071 RR_OtherProjectInfo_1_2-1.2.pdf
46071 RR_KeyPersonExpanded_1_2-1.2.pdf
46071 PHS398_CoverPageSupplement_1_4-1.4.pdf
46071 PHS398_ResearchPlan_1_3-1.3.pdf
46071 PHS398_Checklist_1_3-1.3.pdf
Optional forms
46071 PHS_CoverLetter_1_2-1.2.pdf
46071 PHS398_ModularBudget-1.1.pdf
46071 RR_Budget-1.1.pdf
46071 RR_SubawardBudget-1.2.pdf
Package 3
Mandatory forms
46071 RR_SF424_1_2-1.2.pdf
46071 RR_OtherProjectInfo_1_3-1.3.pdf
46071 RR_KeyPersonExpanded_1_2-1.2.pdf
46071 PerformanceSite_1_4-1.4.pdf
46071 PHS398_ResearchPlan_1_3-1.3.pdf
46071 PHS398_CoverPageSupplement_1_4-1.4.pdf
46071 PHS398_Checklist_1_3-1.3.pdf
Optional forms
46071 RR_Budget-1.1.pdf
46071 RR_SubawardBudget-1.2.pdf
46071 PHS_CoverLetter_1_2-1.2.pdf
46071 PHS398_ModularBudget-1.1.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
